Its inhibition decreased the viability of HCC cells and increased sorafenib‐induced cell death.[67] cPLX2 stimulated nuclear factor E2‐related factor 2 (NRF2) expression and inhibited ferroptosis, thereby inhibiting HCC cell proliferation, migration, and invasion. Here, CPLX2 is linked to hepatocellular carcinoma.